BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 34225440)

  • 1. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research advances in diagnosis of non-alcoholic fatty liver disease].
    Wang JH; Yu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):115-118. PubMed ID: 28297797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.
    Perakakis N; Stefanakis K; Mantzoros CS
    Metabolism; 2020 Oct; 111S():154320. PubMed ID: 32712221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
    Perakakis N; Polyzos SA; Yazdani A; Sala-Vila A; Kountouras J; Anastasilakis AD; Mantzoros CS
    Metabolism; 2019 Dec; 101():154005. PubMed ID: 31711876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
    Alkhouri N; Feldstein AE
    Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease.
    Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
    Curr Pharm Des; 2020; 26(32):3928-3938. PubMed ID: 32436818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histopathological diagnosis and differential diagnosis of nonalcoholic fatty liver disease].
    Theurer S; Kälsch J; Schwertheim S; Kathemann S; Baba HA
    Pathologe; 2020 Sep; 41(5):434-443. PubMed ID: 32533233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease.
    Zeng Y; He H; An Z
    Dis Markers; 2022; 2022():1254014. PubMed ID: 35811662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD).
    Carulli L; Zanca G; Schepis F; Villa E
    Metabolites; 2019 Feb; 9(2):. PubMed ID: 30717274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.
    Albhaisi S; Sanyal AJ
    Pharmaceut Med; 2019 Dec; 33(6):451-463. PubMed ID: 31933238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of liver biopsy in nonalcoholic fatty liver disease.
    Nalbantoglu IL; Brunt EM
    World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.